Summit Therapeutics (SMMT) reported a Q4 non-GAAP net loss Monday of $0.07 per diluted share, widening from a loss of $0.04 a year earlier.
Analysts polled by FactSet expected a loss of $0.08.
The biopharmaceutical company did not report any revenue.
The company reported cash, cash equivalents and short-term investments of $412.3 million as of Dec. 31, up from $186.2 million a year earlier.
Summit shares were up nearly 11% in recent premarket activity
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.